

## Intas Pharmaceuticals collaborates with IntegriMedical

29 December 2025 | News

### To offer IVF and gynecology therapies with needle-free injections



Ahmedabad-based Intas Pharmaceuticals has entered into an exclusive agreement with IntegriMedical, the technology leader behind India's first Needle-Free Injection System (N-FIS), to introduce this revolutionary technology for use in IVF and gynecology treatments across India.

This marks a significant milestone in IVF and women's health. Securing exclusivity for a first-of-its-kind needle-free injector transforms both the delivery and experience of treatment, placing patient comfort and confidence at the forefront of care.

Through this agreement, Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections, setting a new benchmark for patient-centric innovative drug delivery system. The collaboration represents a decisive step in transforming how reproductive care is delivered.

By leveraging IntegriMedical's proprietary drug-delivery technology, Intas aims to reduce injection-related discomfort and anxiety while enhancing compliance and patient satisfaction. Under the agreement, Intas, in collaboration with IntegriMedical, will streamline deployment of needle-free injections across IVF clinics and gynecology centers nationwide.

India represents one of the fastest-growing IVF markets globally. Reportedly, the current number is around 300,000 to 350,000 cycles per year, with projections suggesting this could increase to 500,000 to 600,000 cycles by 2027. At scale, this results in several million injections administered every year as part of IVF treatment in India alone. By integrating needle-free injection technology into IVF treatment pathways, the collaboration is expected to improve the treatment experience for hundreds of thousands of women annually, particularly by reducing injection-related pain, anxiety, and treatment fatigue.

*Image credit- L-R- Sarvesh Mutha, Managing Director, IntegriMedical and Durga P Satapathy, Executive Vice President, Intas Pharmaceuticals*